Начало・Списък с акции・AnaptysBio Inc

AnaptysBio Inc

Затворен

СекторЗдравеопазване

53.16 -3.5

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

51.59

Максимум

55.13

Ключови измерители
By Trading Economics
Приходи	-102M -53M
Продажби	-83M 26M
EPS	-1.843
Марж на печалбата	-206.934
Служители	104
EBITDA	-99M -31M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+46.57% upside

Дивиденти
By Acuity
Следващи печалби	4.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-389M 1.6B
Предишно отваряне	56.66
Предишно затваряне	53.16

Настроения в новините

By Acuity

50%

162 / 340 Класиране в Healthcare

AnaptysBio Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

30.07.2026 г., 23:36 ч. UTC

AnaptysBio Inc. shares declined after-market, reflecting ongoing weakness amid broader market volatility and the Federal Reserve's interest rate decisions.

29.07.2026 г., 19:56 ч. UTC

Macro Event

AnaptysBio Inc shares are higher, recovering from an earlier dip, amid market volatility following the Federal Reserve's decision to maintain interest rates steady.

28.07.2026 г., 23:16 ч. UTC

AnaptysBio Inc shares are higher in after-market trading, recovering from earlier lows. No specific news was identified to explain the movement.

24.07.2026 г., 19:16 ч. UTC

AnaptysBio Inc shares are lower today, reflecting a decline since Thursday. Broader market sentiment is affected by recent volatility in oil prices.

23.07.2026 г., 09:16 ч. UTC

AnaptysBio Inc is trading lower in pre-market hours amid broader market pressures from disappointing earnings reports and rising geopolitical tensions.

22.07.2026 г., 22:16 ч. UTC

AnaptysBio Inc shares are higher in after-market hours, trading above Wednesday's close amid broader market concerns over rising crude oil prices and U.S.-Iran tensions.

21.07.2026 г., 20:12 ч. UTC

AnaptysBio Inc. shares are lower in after-market trading, continuing a downward trend and positioning the stock below its 20-day moving average.

20.07.2026 г., 23:01 ч. UTC

AnaptysBio Inc. shares are higher in after-market trading, reflecting routine activity. The stock remains below its 20-day moving average.

Сравнение с други в отрасъла

Ценова промяна

AnaptysBio Inc Прогноза

Ценова цел

By TipRanks

46.57% нагоре

12-месечна прогноза

Среден 80.67 USD 46.57%

Висок 95 USD

Нисък 70 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за AnaptysBio Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

7 ratings

Купи

Задържане

Продай

Според 7 анализатори, дали борсови рейтинги на AnaptysBio Inc през последните 3 месеца.

Настроение

By Acuity

162 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.